Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens
AUTOR(ES)
Jones, Ronald N.
FONTE
American Society for Microbiology
RESUMO
Doripenem (formerly S-4661), a new 1-β-methyl carbapenem, was challenged with a worldwide collection of 394 drug-refractory isolates. For endemic extended-spectrum β-lactamase- and stably derepressed AmpC-producing enteric bacilli, the doripenem MICs at which 90% of the isolates were inhibited (MIC90s) were 0.03 to 0.5 μg/ml, generally lower than those of comparator carbapenems. A greater proportion of strains among carbapenem-resistant nonfermentative gram-negative bacilli were inhibited by doripenem at ≤4 μg/ml, and doripenem was the most active carbapenem (MIC90, 1 to 4 μg/ml) against penicillin-resistant streptococci.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=478547Documentos Relacionados
- Drug-resistant tuberculosis
- Antimycobacterial activities of antisense oligodeoxynucleotide phosphorothioates in drug-resistant strains.
- Clinical and epidemiological profiles of individuals with drug-resistant tuberculosis
- Phenotypic conversion of drug-resistant bacteria to drug sensitivity
- Drug-resistant bacteria in Continental Shelf sediments.